Life Science Company News

DSM Finalizes Repurchase of Shares to Cover Existing Option Plans and Stock Dividends

HEERLEN, the Netherlands, November 17, 2017 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials, has repurchased 151,900 of its own shares in the period from 10 November 2017 up to and including 14 November 2017 at an average price of 75.63. This is in accordance with the repurchase, covering existing option plans and stock dividends, announced on 14 August 2017. The consideration of this repurchase was 11.5 million. 

     (Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )

This repurchase concludes the program to repurchase 1,600,000 shares for a total consideration of €109.3 million.

For more detailed information see the 'Daily transaction details 1.6m Share Repurchase Program announced 14 August 2017'.

DSM - Bright Science. Brighter Living.™ 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.


Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

media.contacts@dsm.com

http://www.dsm.com

For more information:
DSM Corporate Communications
Stephen Hufton
tel. +31-(0)-45-5782421        
e-mail media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31-(0)-45-5782864
e-mail investor.relations@dsm.com

 

PDF - http://mma.prnewswire.com/media/606608/DSM_finalizes_repurchase_of_shares.pdf

 

PRN NLD

- 17 Nov 2017
Back to overview

Enhance your business development with Biotechgate